Optimizing Durability of Allogeneic CAR T Therapy in Non-Hodgkin Lymphoma: Update on 1st and 2nd Gen CD19 Programs June 4, 2021 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation (together with any other statements or information that we may make in connection herewit ...